Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9962 |
Mepolizumab
美泊利单抗,SB 240563 |
IL Receptor | Immunology/Inflammation |
Mepolizumab (SB 240563) 是一种中和 IL-5 的人源化单克隆抗体。 美泊利单抗可用于严重嗜酸性哮喘和嗜酸性肉芽肿伴多血管炎的研究。 | |||
T10497 |
Benralizumab
BIW-8405,MEDI-563 |
Apoptosis; IL Receptor; Interleukin | Apoptosis; Immunology/Inflammation |
Benralizumab (MEDI-563) 是一种靶向白介素 5 受体 α (IL-5Rα) 单克隆抗体,通过增强抗体依赖性细胞介导的细胞毒性促使嗜酸性粒细胞快速进行反应。Benralizumab 可用于严重的嗜酸性哮喘,可用于预防慢性阻塞性肺病加重。 | |||
TP2008L |
Lyn peptide inhibitor acetate
Lyn peptide inhibitor acetate(222018-18-0 free base) |
IL Receptor | Immunology/Inflammation |
Lyn peptide inhibitor acetate(222018-18-0 free base) 是一种有效的细胞渗透性 Lyn 偶联 IL-5 受体信号通路抑制剂,同时保持其他信号完整。它阻断 Lyn 活化并抑制 Lyn 酪氨酸激酶与 IL-3/GM-CSF/IL-5 受体的 βc 亚基的结合。它可用于哮喘、过敏和其他嗜酸性粒细胞疾病的研究。 | |||
T12706 |
Reslizumab
Sch 55700 |
IL Receptor | Immunology/Inflammation |
Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. | |||
T11521 |
GW 766994
GW 994 |
CCR | Immunology/Inflammation; Microbiology/Virology |
GW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist. It has the potential for asthma and eosinophilic bronchitis treatment. | |||
T30535 |
BMS-639623
UNII-PON9OFP69G,PON9OFP69G,BMS 639623,CHEMBL399495 |
||
BMS-639623 is a CCR3 antagonist with a picomolar inhibitory effect on eosinophilic chemotaxis and can be used in the treatment of asthma. | |||
TP2008 |
Lyn peptide inhibitor
|
||
Cell-permeable inhibitor of Lyn-dependent effects of the IL-5 receptor. Blocks binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors, blocking Lyn activation. Inhibits IL-5 receptor-mediated eosinophil differentiation and survival in | |||
T75806 |
Lyn peptide inhibitor TFA
|
||
Lyn peptide inhibitor TFA 是一种有效的,可以细胞渗透的抑制剂,抑制Lyn 偶联的IL-5受体相关信号通路,同时保持其他信号的完整。Lyn peptide inhibitor TFA 可以阻断 Lyn 的激活,抑制 Lyn 酪氨酸激酶与 IL-3/GM-CSF/IL-5 受体的 βc 亚基结合。Lyn peptide inhibitor TFA 可用于哮喘、过敏等嗜酸性疾病的研究。 | |||
T76942 | Cendakimab | ||
Cendakimab (RPC4046; ABT 308; CC-93538)为一种选择性人源化IL-13重组单克隆抗体,对人野生型和变异型IL-13显示出高亲和力和效力。该抗体通过阻断IL-13与IL-13Rα1及IL-13Rα2的结合,抑制作用力分别在ELISA测定中的IC50值为352 pM与631 pM。Cendakimab还能识别野生型和R110Q多态变体IL-13,其结合亲和力分别为52 pM与50 pM。其显示出针对IL-13相关过敏/炎症性疾病的潜在治疗作用,如哮喘和嗜酸性粒细胞性食管炎。 |